The results of this analysis were in line with those for the full HbA1c and weight cohorts, supporting the key conclusions of our analysis
We look forward to bringing this product to market in the very near future. About Orbicular Orbicular is an R&D focussed, partnership driven B2B specialty pharmaceutical platform, developing and licensing IP-owned assets in complex generics and advanced drug delivery systems across global markets
Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes
Comparison with Other Similar Medications Semaglutide belongs to a group of medications called GLP-1 receptor agonists
Originally developed to manage Type 2 diabetes, Tirzepatide also impacts key hormones involved in hunger and energy regulation, making it highly effective for weight loss
Withdrawal effects When GLP1s are stopped, patients may experience a range of physical symptoms